Novocure receives FDA not approvable letter for Optune Mya in brain metastases from NSCLC

Novocure received a Not Approvable letter from the FDA in response to its PMA application for Optune Mya for treating adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.

Detected & updated continuously · Source: Nebula